SUNHAWK BIO

7759 · TWO · Healthcare / Biotechnology

59.30TWD+9.00 (+17.89%)

Price History

Full chart

Market Stats

Previous Close50.30

Open51.20

Day Range50.20 – 59.40

52-Week Range25.60 – 77.30

Volume145.58K

Market Cap2.99B

P/E (TTM)0.00

Forward P/E0.00

EPS-1.89

Dividend Yield0.00%

50-Day Avg32.73

200-Day Avg39.21

About

Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren's syndrome, as well as in a Phase 2 clinical trial for myopia control in young children. Sunhawk Vision Biotech, Inc. was founded in 2019 and is based in Taipei, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Suh-Hang Juo
HeadquartersNo.66, Sanchong Road, Taipei, Taiwan, 115602, Taiwan
Websitehttps://sunhawkvision.com

Leadership

Dr. Suh-Hang JuoFounder, Chairman & GM
Dr. Chung-Ling LiangFounder, VP, Chief Medical Officer & Director
Mr. Hao-Yu LinVP, Accounting Supervisor & CFO

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	952.00K	0	0	-	-
Growth (%)	-	-100.00%	-	-	-
Operating Income	-39.63M	-15.55M	-113.07M	-101.15M	-175.37M
Operating Margin	-4163.24%	-	-	-	-
EBITDA	-	-15.15M	-96.56M	-82.19M	-166.46M
Net Income	-39.12M	-15.18M	-25.10M	-87.85M	-172.39M
Net Income Margin	-4109.24%	-	-	-	-
R&D	34.55M	12.08M	87.04M	76.13M	151.34M
R&D as % of Total Revenue	3629.62%	-	-	-	-
Interest Expense	-	0	21.00K	194.00K	179.00K

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	109.22M	142.51M	320.85M	308.78M	498.81M
Total Liabilities	1.70M	166.00K	11.29M	12.60M	27.01M
Total Equity	107.52M	142.34M	309.56M	296.18M	471.80M
Cash	11.93M	22.83M	175.07M	111.40M	401.02M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-33.87M	-24.10M	-75.11M	-95.01M	-144.89M
Capital Expenditure	0	0	3.32M	1.05M	415.00K
Free Cash Flow	-33.87M	-24.10M	-78.43M	-96.06M	-145.31M
FCF to OCF	100.00%	100.00%	104.42%	101.11%	100.29%

Key Statistics & Ratios

Market Cap2.99B

Enterprise Value2.61B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book7.08

EPS-1.89

Book Value5.94

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-148.66M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-27.29%

Return on Assets-18.43%

Shares Outstanding70.34M

Shares Float26.91M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%